MedPath

Niacin

Generic Name
Niacin
Brand Names
Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
Drug Type
Small Molecule
Chemical Formula
C6H5NO2
CAS Number
59-67-6
Unique Ingredient Identifier
2679MF687A
Background

Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.

Indication

Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.

Associated Conditions
Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
Associated Therapies
Dietary supplementation
Clinical Trials
Related News

Regulation of Endogenous Glucose Production by Central KATP Channels

Phase 2
Recruiting
Conditions
Glucose, High Blood
Type 2 Diabetes Mellitus
Glucose Metabolism Disorders
Interventions
Drug: Placebo
First Posted Date
2018-05-30
Last Posted Date
2025-04-01
Lead Sponsor
Meredith Hawkins
Target Recruit Count
100
Registration Number
NCT03540758
Locations
🇺🇸

Albert Einstein College of Medicine, Bronx, New York, United States

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

First Posted Date
2018-04-27
Last Posted Date
2023-05-06
Lead Sponsor
Sanofi
Target Recruit Count
153
Registration Number
NCT03510884
Locations
🇪🇸

Investigational Site Number :7240003, Pamplona, Navarra, Spain

🇵🇱

Investigational Site Number :6160002, Gdansk, Pomorskie, Poland

🇲🇽

Investigational Site Number :4840007, Oaxaca, Mexico

and more 40 locations

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

First Posted Date
2018-04-27
Last Posted Date
2020-12-29
Lead Sponsor
Sanofi
Target Recruit Count
18
Registration Number
NCT03510715
Locations
🇩🇰

Investigational Site Number 2080001, Viborg, Denmark

🇪🇸

Investigational Site Number 7240001, A Coruna, Spain

🇸🇮

Investigational Site Number 7050001, Ljubljana, Slovenia

and more 7 locations

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

Phase 1
Completed
Conditions
Obsessive-Compulsive Disorder
Interventions
First Posted Date
2017-11-29
Last Posted Date
2024-11-20
Lead Sponsor
Yale University
Target Recruit Count
31
Registration Number
NCT03356483
Locations
🇺🇸

Connecticut Mental Health Center, New Haven, Connecticut, United States

The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis

Phase 4
Conditions
Hyperphosphatemia
Interventions
First Posted Date
2017-05-23
Last Posted Date
2017-05-23
Lead Sponsor
Assiut University
Target Recruit Count
150
Registration Number
NCT03163576

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

First Posted Date
2016-09-07
Last Posted Date
2019-09-06
Lead Sponsor
Sanofi
Target Recruit Count
42
Registration Number
NCT02890992
Locations
🇨🇿

Investigational Site Number 2030002, Zlin, Czechia

🇺🇸

Investigational Site Number 8400005, Charlotte, North Carolina, United States

🇺🇸

Investigational Site Number 8400001, Cincinnati, Ohio, United States

and more 13 locations

Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)

Not Applicable
Completed
Conditions
Impaired Glucose Tolerance
Interventions
Procedure: Biopsy
Other: [7,7,8,8-2H]-palmitate
Other: liquid meal
Other: [U-13C]-palmitate
First Posted Date
2016-06-21
Last Posted Date
2025-01-27
Lead Sponsor
Université de Sherbrooke
Target Recruit Count
50
Registration Number
NCT02808182
Locations
🇨🇦

centre de recherche du CHUS, Sherbrooke, Quebec, Canada

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

Phase 1
Terminated
Conditions
Solid Tumors
NHL
Interventions
First Posted Date
2016-03-08
Last Posted Date
2024-11-25
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
60
Registration Number
NCT02702492
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

UCLA Health, Los Angeles, California, United States

🇺🇸

University of Colorado Cancer Center, Aurora, Colorado, United States

and more 5 locations

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Phase 4
Completed
Conditions
Dyslipidemia
Interventions
Drug: Statins
Drug: Antihyperglycemic Drug
First Posted Date
2015-12-30
Last Posted Date
2018-05-01
Lead Sponsor
Sanofi
Target Recruit Count
413
Registration Number
NCT02642159
Locations
🇺🇸

Investigational Site Number 840-156, Tustin, California, United States

🇫🇮

Investigational Site Number 246101, Oulu, Finland

🇺🇸

Investigational Site Number 840-118, Los Angeles, California, United States

and more 116 locations

Safety, Tolerability and Efficacy Study of PP1420 in HV

Phase 1
Terminated
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2014-08-20
Last Posted Date
2021-09-22
Lead Sponsor
Imperial College London
Target Recruit Count
49
Registration Number
NCT02221765
Locations
🇬🇧

NIHR/ Wellcome Trust Imperial Clinical Research Facility, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy